公开(公告)号：CA2697583C

公开(公告)日：2016-04-12

申请号：CA2697583

申请日：2008-09-26

Applicant: PORTOLA PHARM INC

Inventor： LU GENMIN ,  PHILLIPS DAVID R ,  ANDRE PATRICK ,  SINHA UMA

IPC: C12N9/64 ,  A61K31/4545 ,  A61K31/5377 ,  A61K31/715 ,  A61K31/727 ,  A61K38/36 ,  A61K38/48 ,  A61K39/00 ,  A61K39/395 ,  A61K47/48 ,  A61P7/02 ,  A61P7/04 ,  C07H21/00 ,  C07K14/00 ,  C07K16/00 ,  C12N5/10 ,  C12P21/00

Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.

公开(公告)号：AU2014210620A1

公开(公告)日：2014-08-28

申请号：AU2014210620

申请日：2014-08-07

Applicant: PORTOLA PHARM INC

Inventor： LU GENMIN ,  PHILLIPS DAVID R ,  ANDRE PATRICK ,  SINHA UMA

IPC: A61P7/02 ,  A61K31/4545 ,  A61K31/5377 ,  A61K31/715 ,  A61K31/727 ,  A61K38/36 ,  A61K38/48 ,  A61K39/00 ,  A61K39/395 ,  A61K47/48 ,  A61P7/04 ,  C07H21/00 ,  C07K14/00 ,  C07K16/00 ,  C12N5/10 ,  C12N9/64 ,  C12P21/00

Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.

公开(公告)号：SG185263A1

公开(公告)日：2012-11-29

申请号：SG2012072716

申请日：2008-09-26

Applicant: PORTOLA PHARM INC

Inventor： LU GENMIN ,  PHILLIPS DAVID R ,  ANDRE PATRICK ,  SINHA UMA

IPC: A61K39/00

Abstract: AbstractANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.Figure 13.

公开(公告)号：AU2005235289B2

公开(公告)日：2010-10-28

申请号：AU2005235289

申请日：2005-04-18

Applicant: PORTOLA PHARM INC

Inventor： ANDRE PATRICK ,  HOMCY CHARLES ,  PHILLIPS DAVID R

IPC: A61K31/4745 ,  A61F2/02 ,  A61K31/473 ,  A61K31/52

Abstract: The present invention provides novel compositions and methods for inhibiting restenosis, thrombosis, and/or inflammation in a patient undergoing a vascular intervention. More particularly, the present invention provides intravascular devices coated with one or more spleen tyrosine kinase (Syk) inhibitors. Methods for inhibiting restenosis, thrombosis, and/or inflammation in a patient by treatment with such intravascular devices are also provided. In addition, the present invention provides methods for treating sickle cell disease using Syk inhibitors.

公开(公告)号：MX2010003095A

公开(公告)日：2010-04-09

申请号：MX2010003095

申请日：2008-09-26

Applicant: PORTOLA PHARM INC

Inventor： PHILLIPS DAVID R ,  ANDRE PATRICK ,  LU GENMIN ,  SINHA UMA

IPC: A61K39/00 ,  C12N9/64 ,  A61P7/04

Abstract: La presente invenci?n se refiere a ant?dotos para anticoagulantes que fijan como objetivo el factor Xa. Los ant?dotos son derivados de prote?nas del factor Xa que se enlazan a los inhibidores del factor Xa neutraliz?ndolos sustancialmente en consecuencia pero no ensambl?ndose en el complejo de protrombinasa. Los derivados descritos en este documento carecen o tienen actividad coagulante intr?nseca reducida. Se dan a conocer en este documento m?todos para detener o prevenir el sangrado en un paciente que est? someti?ndose actualmente a terapia anticoagulante con un inhibidor del factor Xa.

公开(公告)号：MX2009011744A

公开(公告)日：2010-02-12

申请号：MX2009011744

申请日：2008-05-02

Applicant: PORTOLA PHARM INC

Inventor： PHILLIPS DAVID R ,  STEPHENS GILLIAN ,  GAO DACAO ,  ANDRE PATRICK

IPC: A01N37/10 ,  A61K31/19

Abstract: La presente invención proporciona nuevos métodos para tratar trombosis y enfermedades cardiovasculares usando agentes antitrombóticos, así como métodos para determinar cantidades terapéuticamente efectivas de agentes antitrmobóticos y formulaciones de dosis unitaria de los mismos.

公开(公告)号：CA2562734A1

公开(公告)日：2005-11-03

申请号：CA2562734

申请日：2005-04-18

Applicant: PORTOLA PHARM INC

Inventor： ANDRE PATRICK ,  PHILLIPS DAVID R ,  HOMCY CHARLES

IPC: A61F2/02 ,  A61K31/473 ,  A61K31/4745 ,  A61K31/52

Abstract: The present invention provides novel compositions and methods for inhibiting restenosis, thrombosis, and/or inflammation in a patient undergoing a vascul ar intervention. More particularly, the present invention provides intravascula r devices coated with one or more spleen tyrosine kinase (Syk) inhibitors. Methods for inhibiting restenosis, thrombosis, and/or inflammation in a patient by treatment with such intravascular devices are also provided. In addition, the present invention provides methods for treating sickle cell disease using Syk inhibitors.

公开(公告)号：AU2021218033A1

公开(公告)日：2021-09-09

申请号：AU2021218033

申请日：2021-08-17

Applicant: PORTOLA PHARM INC

Inventor： LU GENMIN ,  PHILLIPS DAVID R ,  ANDRE PATRICK ,  SINHA UMA

IPC: A61P7/02 ,  A61K31/4545 ,  A61K31/5377 ,  A61K31/715 ,  A61K31/727 ,  A61K38/36 ,  A61K38/48 ,  A61K39/00 ,  A61K39/395 ,  A61P7/04 ,  C07H21/00 ,  C07K14/00 ,  C07K16/00 ,  C12N5/10 ,  C12N9/64 ,  C12P21/00

Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or 5 have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.

公开(公告)号：ES2597436T3

公开(公告)日：2017-01-18

申请号：ES08834136

申请日：2008-09-26

Applicant: PORTOLA PHARM INC

Inventor： LU GENMIN ,  PHILLIPS DAVID R ,  ANDRE PATRICK ,  SINHA UMA

IPC: A61K38/48 ,  A61K39/00 ,  A61P7/04 ,  C12N9/64

Abstract: Un derivado de fXa que es un polipéptido aislado que comprende la secuencia de aminoácidos de la SEQ ID NO. 12.

公开(公告)号：CA2627719C

公开(公告)日：2016-07-12

申请号：CA2627719

申请日：2006-11-03

Applicant: PORTOLA PHARM INC

Inventor： HUANG WOLIN ,  MEHROTRA MUKUND ,  ZHANG XIAOMING ,  CANNON HILARY ,  GRANT CRAIG M ,  SCARBOROUGH ROBERT M ,  PANDEY ANJALI ,  CONLEY PAMELA B ,  ANDRE PATRICK ,  PHILLIPS DAVID R ,  SINHA UMA

IPC: C07D409/12 ,  A61K31/517 ,  A61P7/02 ,  A61P9/00 ,  C07C269/04 ,  C07C271/58 ,  C07D239/96

Abstract: The present invention provides novel sulfonylurea compounds of formula (I) and pharmaceutically acceptable derivatives and polymorph and amorphous forms thereof. The compounds in their various forms are effective platelet ADP receptor inhibitors and may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also provides a method for preparing such compounds and forms and for preventing or treating thrombosis and thrombosis related conditions in a mammal comprising the step of administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or forms thereof.